Navigation Links
Gamma-Tocotrienol Kills Prostate Cancer Stem Cells
Date:7/25/2010

SINGAPORE, July 25 /PRNewswire-Asia/ -- Scientists from Singapore, Australia and Hong Kong have found that gamma-tocotrienol is potent in killing prostate cancer stem cells. This small group of cells is responsible for the initiation of prostate cancer and is resistant to conventional chemotherapy drugs. It causes relapses in the cancer by producing new chemo-resistant cancer cells. Gamma-tocotrienol is a member of the Vitamin E family and is derived naturally from palm oil.

This study aimed to find a way to eradicate prostate cancer stem cells. It follows an earlier report that demonstrated the effectiveness of gamma-tocotrienol in targeting the bulk of the prostate tumour mass. This latest finding highlights the considerable potential of gamma-tocotrienol as a natural remedy to prevent and treat prostate cancer.

This research study involves collaboration between scientists at Davos Life Science (Singapore) and researchers at Australian Prostate Cancer Research Centre -- Queensland and The Hong Kong University. The findings were reported in the latest edition of the International Journal of Cancer (IJC).

The scientists found that low doses of gamma-tocotrienol cause apoptosis in the prostate cancer stem cells and suppress their colony formation capability. This results in a lower prostate cancer stem cell population (as defined by the protein markers CD133 and CD44). Further tests in mice models were conducted, where mice implanted with hormonal refractory prostate cancer cells were given gamma-tocotrienol orally. The results showed that gamma- tocotrienol not only reduced tumour size formed, but also decreased the incidence rate of tumour formation by 75%, as compared to the control group of mice, which had 100% tumour formation. These results strongly suggest that gamma-tocotrienol could be developed for prostate cancer prevention and treatment.

"Current chemotherapy drugs, such as Docetaxel, have limited effect on prostate cancer stem cells, although they are currently the first-line drug given to patients with advanced hormonal refractory prostate cancer. This study shows that gamma-tocotrienol is effective in preventing the formation of prostate tumours in mice models. The key compound involves the use of a natural product, gamma-tocotrienol, which is found in edible plant oils, thereby minimising potential adverse side effects," said Dr. Daniel Yap, one of the leading scientists for the study and Head of Research & Development at Davos Life Science. "As gamma-tocotrienol has shown positive results in removing the stubborn prostate cancer stem cells, it should be investigated as a more effective form of treatment strategy to achieve what conventional chemotherapy drug has failed to do -- to keep the disease in remission state."

"These results provide a compelling case for developing the potential of gamma-tocotrienols to help patients with terminal hormonal refractory prostate cancer. The prospects of future studies on the cancer-fighting effects of gamma-tocotrienols are exciting indeed and we see increasing research interest by scientists in this area," said Mr. Arthur Ling, CEO of Davos Life Science Singapore.

About Davos Life Science

Davos Life Science was established in 2004 as the world's largest tocotrienol manufacturer. The company extracts natural palm tocotrienols for use in health supplements, functional foods, personal care products and pharmaceutical formulations under the brand name "Natural e3". The company has also set up the world largest research and development centre dedicated to tocotrienols. For more information, please visit http://www.davoslife.com


'/>"/>
SOURCE Davos Life Science
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vision Problems Affect How Children Learn Math Skills
2. Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
3. Program Improves Language Skills in Deaf, Hard of Hearing
4. Hand Washing with 4% CHG Antiseptic Kills Flu Viruses
5. Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
8. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... ZappRx, Inc ., a digital health company focused on modernizing ... closed $25 million in Series B funding led by Qiming ... Seattle that is part of a broader ... round included participation from SR One , who led ... (formerly Google Ventures). As part of the financing, Mark ...
(Date:4/20/2017)... April 20, 2017 Eyevensys, a ... first non-viral gene expression technology that enables the safe, ... to address a wide range of ophthalmic diseases, announces ... Healthcare products Regulatory Agency (MHRA) to advance its technology ... ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy ... the preferred physical therapy provider for Derby City CrossFit, effective immediately. , In ... as quickly and effectively as possible, ProRehab’s sports physical therapists will work with ...
(Date:4/25/2017)... ... April 25, 2017 , ... As President Trump ... preparing for how his administration could impact the employee benefits industry. James Slotnick, ... are most likely to make it through Congress. His discussion will focus on ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Lake Park Dental ... by using Invisalign® in Lutz, FL. With the help of this highly-effective, ... aesthetics with fewer potential complications, more discretion and less pain. , Drs. Sarah ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
Breaking Medicine News(10 mins):